{"transactions":[{"id":2638347,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":657985,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the\nmanager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":657985},"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638346,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":1315969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1315969},"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638345,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":1634515,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1634515},"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638344,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":657985,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the\nmanager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":657985,"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638343,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":3352693,"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638342,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:15:57.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":2950484,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":3040193,"source":{"system":"sec-edgar","filing":"0001209191-21-046028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046028/doc4.xml","form_type":"4"}},{"id":2638341,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-08T18:14:53.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":2076326,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and\n1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D.\nHardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each\nentity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the\nextent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2076326},"source":{"system":"sec-edgar","filing":"0001209191-21-046027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046027/doc4.xml","form_type":"4"}},{"id":2638340,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-07-08T18:14:53.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":1124830,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415\nshares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the\nManager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The\nReporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of\nhis pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1124830},"source":{"system":"sec-edgar","filing":"0001209191-21-046027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046027/doc4.xml","form_type":"4"}},{"id":2638339,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:14:53.000Z","date":"2021-07-06","kind":"purchase","acquired":true,"shares":750000,"price":16,"value":12000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of 375,000 shares of common stock held by H7 Holdings LLC, and 375,000 shares of common stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein."}],"balance_after":3951156,"source":{"system":"sec-edgar","filing":"0001209191-21-046027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046027/doc4.xml","form_type":"4"}},{"id":2638338,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:14:53.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":2076326,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and\n1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D.\nHardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each\nentity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the\nextent of his pecuniary interest therein."}],"balance_after":3201156,"source":{"system":"sec-edgar","filing":"0001209191-21-046027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046027/doc4.xml","form_type":"4"}},{"id":2638337,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":137477,"kind":"person","name":"Hardie Robert D.","position":1,"cik":"0001804350","reported_name":"Hardie Robert D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T18:14:53.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":1124830,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415\nshares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the\nManager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The\nReporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of\nhis pecuniary interest therein."}],"balance_after":1124830,"source":{"system":"sec-edgar","filing":"0001209191-21-046027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804350/000120919121046027/doc4.xml","form_type":"4"}}]}